Lentigo maligna survival: balancing treatment decisions in those with limited life expectancy
This study assesses incidence, and overall and net survival in patients with lentigo maligna (LM) in England. Data show excellent 5-year net survival for all ages (> 100%), but overall survival in those aged 80+ years is only 60.4%, reflecting the impact of comorbidities and limited life expectancy. These findings highlight the need for LM management guidelines to incorporate frailty assessment and support shared decision making in older adults, including consideration of nonsurgical approaches.
Authors
- Martyn Patel (ORCID: https://orcid.org/0000-0002-9313-3894)
- James Powell (ORCID: https://orcid.org/0000-0001-7750-4651)
- Birgitta van Bodegraven (ORCID: https://orcid.org/0000-0002-8359-9017)
- Zoe Claire Venables (ORCID: https://orcid.org/0000-0002-9929-2693)
- Dimitrios Karponis (ORCID: https://orcid.org/0000-0002-8847-7537)
- Kate Quirke (ORCID: https://orcid.org/0000-0002-7785-8967)
Institutions
- University of East Anglia (GB)
- Norfolk and Norwich University Hospital (GB)
- British Association of Dermatologists (GB)
- NHS Digital (GB)
- Wye Valley NHS Trust (GB)
- NHS England
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1093/bjd/ljaf489
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.05